US FDA Cancels Panel Review Of Two ‘Delinquent’ Cancer Drug Accelerated Approvals

 
• By Sue Sutter
  
Cancelled sign
Since October, the FDA has cancelled ODAC reviews of accelerated approval drugs Farydak, Marqibo and Pepaxto. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers